Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial.

34 A randomised double-blind, placebo-controlled trial of aciclovir showed a trend towards reduction in annualised relapse rate which when dichotomised to low or high relapse rate became statistically significant. 49 Famciclovir was chosen on the basis of its greater bioavailability, higher intracellular concentration and greater persistence in infected cells. 35 Dose and administration SOC plus Spironolactone: - Spironolactone 50 mg twice daily administered orally Spironolactone is approved for the treatment of essential hypertension, congestive heart failure, cirrhotic liver disease and nephrotic syndrome.

also in 53,322 other papers